Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate Apr. 10, 2024 5:12 AM ET Recursion Pharmaceuticals, Inc. (RXRX) Stock RXRX 4 Comments 3 Likes Nelson Alves ...

One outcome of the big data efforts is a new, publicly available data set that Recursion released in May, called the RxRx1. It consists of 300 gigabytes of over 100,000 images "representing ...

Powered by Recursion's NVIDIA supercomputer for its training and validation, this next-generation AI model achieves best-in-class accuracy in jointly modeling complex structures and binding ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...

Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify ...

SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S.

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but ...